Engineered E. coli vesicles act as vaccine deliverers

June 7, 2016 by Tom Fleischman, Cornell University
Escherichia coli. Credit: Rocky Mountain Laboratories, NIAID, NIH

Mention E. coli and what pops into most people's heads are bacteria, tainted food, a rush to the hospital – basically, fear.

"E. coli gets a bad rap – and rightfully so," said Matthew DeLisa, the William L. Lewis Professor of Engineering.

But, as with many things, there are good varieties of E. coli and dangerous ones. And DeLisa, whose research focuses on developing tools for investigating and manipulating biological machinery directly in living bacterial cells, is working on a way to use a domesticated lab strain of E. coli to create and deliver vaccines.

A multi-institution effort – involving researchers from Cornell and the universities of Iowa, Texas and Georgia – has resulted in a paper that details how antigen-coated derived from the surface of E. coli cells protected mice from a deadly pathogen, and how that system could work against other pathogens, as well.

The group's paper, "Outer membrane vesicles displaying engineered glycotypes elicit protective antibodies," was published online June 6 in the Proceedings of the National Academy of Sciences.

DeLisa, a member of the editorial board of the journal Cell Chemical Biology, has been engineering bacteria cells to do things they don't normally do for quite some time. His startup company, Glycobia, was the first to commercialize the use of engineered bacteria to make human glycoproteins – a protein modified with a carbohydrate attachment.

DeLisa and co-author David Putnam, associate professor in the Nancy E. and Peter C. Meinig School of Biomedical Engineering, have been working together for a decade on glycoproteins, or glycans – a protein with a carbohydrate attachment, which can be used to bind to certain protein receptor sites and, for example, block cancer cells from multiplying.

In this latest work, DeLisa's group has taken a similar approach to generating designer carbohydrate structures in E. coli, but instead of transferring the glycan to a protein, the cells assemble the glycan on a specific lipid carrier molecule. From there, the molecule is shuttled to the of the E. coli cell, which then sheds small portions of that membrane.

"So you start with a 1-micron bacterial cell, and following vesiculation you get these small nanometer-scale spheres known as outer membrane vesicles (OMVs) that come off," DeLisa said. "Because they shed directly from the outer membrane of the cell, these OMVs are membrane-based nanostructures whose outer surfaces mimic the originating cell. So whatever is on the surface of the bacterial cell – say, an engineered glycolipid – becomes present on the surface of these vesicles."

These "conjugate" vaccines were injected into mice infected with the Francisella tularensis Schu S4 bacterium, the causative agent of tularemia and a feared bioweapon. That particular pathogen was chosen, DeLisa said, because of its potency and the lack of an existing vaccine.

"We might have chosen easier, lower-hanging fruit in terms of target pathogens," he said, "However, the lethality of Schu S4 – less than 10 colony-forming units are enough to kill you – made this organism a more interesting challenge."

Infected mice treated with the conjugate vesicle vaccines survived much longer than the control group. And in separate challenge experiments with a less virulent strain of Francisella, the vaccinated group saw 100 percent protection and survival of all mice.

A major advantage of OMVs as vaccine candidates is that they are potent adjuvants, which means they enhance the body's immune response to the co-delivered antigen.

"We think there's a real opportunity to further engineer these nanovesicles to go after other highly challenging vaccine targets," he said. "It's been fun and rewarding, because it brings together several research topics that we've been working on for a while now so we can leverage all that expertise."

Explore further: New tool identifies therapeutic proteins in a 'snap'

More information: Linxiao Chen et al. Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies, Proceedings of the National Academy of Sciences (2016). DOI: 10.1073/pnas.1518311113

Related Stories

New tool identifies therapeutic proteins in a 'snap'

August 21, 2014

( —In human and bacterial cells, glycosylation – the chemical process of attaching complex sugar molecules to proteins – is as fundamental as it gets, affecting every biological mechanism from cell signaling ...

All change for bacterial outer membrane proteins

June 10, 2015

The discovery of how a group of bacteria rapidly adapts to changing growth conditions could have implications for future antibiotic development, according to research at the University of Oxford and the University of York.

Antibody-making bacteria promise drug development

August 31, 2015

Monoclonal antibodies, proteins that bind to and destroy foreign invaders in our bodies, routinely are used as therapeutic agents to fight a wide range of maladies including breast cancer, leukemia, asthma, arthritis, psoriasis, ...

Recommended for you

What happened before the Big Bang?

March 26, 2019

A team of scientists has proposed a powerful new test for inflation, the theory that the universe dramatically expanded in size in a fleeting fraction of a second right after the Big Bang. Their goal is to give insight into ...

Cellular microRNA detection with miRacles

March 26, 2019

MicroRNAs (miRNAs) are short noncoding regulatory RNAs that can repress gene expression post-transcriptionally and are therefore increasingly used as biomarkers of disease. Detecting miRNAs can be arduous and expensive as ...

Race at the edge of the sun: Ions are faster than atoms

March 26, 2019

Scientists at the University of Göttingen, the Institut d'Astrophysique in Paris and the Istituto Ricerche Solari Locarno have observed that ions move faster than atoms in the gas streams of a solar prominence. The results ...

Physicists discover new class of pentaquarks

March 26, 2019

Tomasz Skwarnicki, professor of physics in the College of Arts and Sciences at Syracuse University, has uncovered new information about a class of particles called pentaquarks. His findings could lead to a new understanding ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Jun 07, 2016
So the means to deliver this will be what exactly?... Kind of fuzzy on that point.. are we looking at another Florine in the water scam or will it be more like using Mosquitoes as a Vector to deliver vaccinations to just everyone?.. "for their own good".

Paging Dr. Mengele Line 3


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.